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1. Introduction 
The insulin secretion by arginine and leucine appears 
to be mediated through different mechanisms. By using 
isolated rat islets perifused in vitro, arginine (15 mM) 
was shown to provoke no active insulin release except 
for a tiny first phase [l] . Leucine (19 mM), however, 
stimulated sustained insulin secretion with apparent 
biphasic pattern [2]. Leucine-induced insulin secretion 
is dependent on extracellular calcium and its insulino- 
tropic action is associated with an increased uptake 
of calcium [2]. By adding glucose (8.3 mM) to arginine 
(15 mM), the insulin secretion was three times above 
the baseline secretion [I] . Thus, arginine is the most 
potent glucose dependent ammo acid for stimulating 
insulin secretion [3]. The object of this communica- 
tion was to study arginme- and leucine-induced 
insulin secretion with and without prior exposure to 
alloxan and further, to clarify the possible difference 
of alloxan effect on ammo acid-induced insulin 
secretion. 
2. Materials and methods 
Two hundred islets were isolated from one fed 
Sprague-Dawley rat (200-300 g) by the standard 
collagenase technique [4]. The perifusion system was 
identical to that described in the studies on alloxan 
inhibition of insulin secretion [5]. In brief, two 
chambers were perifused simultaneously: one without 
alloxan exposure served as the control and the other 
with alloxan exposure as the experimental chamber. 
The chambers were maintained at 37°C and perifused 
at a flow rate of 0.7-0.8 ml/mm. The perifusate was 
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collected at one- or five-minute intervals and the 
insulin content of aliquots was determined by the 
radioimmunoassay and was expressed as pU/islet/min 
[S] . The total insulin secretion by the amino acids 
was calculated as mU/ 100 islets/60 min [S] . 
Exposure to alloxan; Alloxan monohydrate (Sigma 
Chemical, St. Louis) was dissolved at a final concen- 
tration of 20 mg% or 40 mg% in previously warmed 
(37°C) and gassed (95% 0,; 5% COa) Krebs-Ringer 
bicarbonate media immediately prior to perifusion. 
L-arginine hydrochloride and L-leucine (both Sigma 
Chemical) were dissolved in bicarbonate media and 
were gassed to maintain at pH 7.4 prior to use. 
3. Results 
Leucine (4 mg/ml = 30.49 mM) induced biphasic 
insulin secretion with first and second phases occurring 
at 6 min and 30 min, respectively (fig.1). Prior 
exposure to alloxan (20 mg%) for 5 min diminished 
leucine-induced insulin secretion to below 1 pU/islet/ 
min; however, small bursts of insulin secretion were 
noted during the exposure to alloxan, immediately 
after changed to leucine medium from glucose medium 
(1 mg/ml) as well as 20-40 min perifusion with 
leucine (fig.1). The exposure to alloxan (40 mg%) for 
5 mm produced similar, but more, inhibition of sub- 
sequent insulin secretion (fig.1). The relative insulin 
secretion after exposure to 20 mg% and 40 mg% 
alloxan, was 52% and 39% of the controls, respectively 
(table 1). 
Arginine hydrochloride (4 mg/ml = 18.98 mM) 
alone induced small but an apparent biphasic secretion 
profile occurring at 5 mm and 25 mm, respectively 
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Fig.1. Two perifusion chambers were perifused simultaneous- 
ly with a 1 mg/ml glucose medium for either 50 min (control 
chambers) or 45 min (experimental chambers). The control 
chambers (thin line) were subsequently followed by perifu- 
sion with a 4 mg/ml leucine for 60 min while the experimental 
chambers (thick line) were introduced with alloxan solution 
for 5 min and were followed by a 4 mg/ml leucine for 60 min. 
Upper: 20 mg% alloxan exposure in the experimental chambers. 
Lower: 40 mg% alloxan exposure in the experimental 
chambers. 
(fig.2). The addition of a non-stimulatory level of 
glucose (0.6 mg/ml) to the arginine solution augmented 
insulin secretion to 8.560 mU/lOO islets/60 min, an 
85% increase compared to arginine alone (table 1). 
Prior exposure to alloxa,r (20 mg%) had little effect 
on arginine and arginine-glucose induced insulin 
secretion, maintaining 92% and 96% of the control 
secretion, respectively (table 1). Furthermore, prior 
exposure to alloxan (40 mg%) did not significantly 
diminish subsequent arginine-glucose induced insulin 
secretion, maintaining 87% of the control secretion 
(table 1). 
4. Discussion 
The dynamics of insulin secretion by arginine and 
leucine have been widely studied with the use of 
perfusion of isolated pancreas [6-lo], pancreatic 
pieces [3] as well as perifusion of isolated islets [2,6, 
11 ,I 21. There was discrepancy on insulin secretion 
by the experimental methods between the isolated 
pancreas and isolated islets. Namely, Norfleet et al. 
reported that arginine (15 mM) alone had no effect 
on the insulin secretion by perifused isolated islets, 
but that it clearly stimulated insulin secretion in a 
perfused isolated pancreas [6]. Gerich et al. however, 
had shown only monophasic insulin release in response 
to argine by perfused isolated pancreas [8]. By peri- 
fusing isolated islets, Charles et al. also demonstrated 
that argine (15 mM) alone caused a tiny first phase of 
insulin secretion [ 121. The addition of non-stimulatory 
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Fig.2. Two chambers were perifused simultaneously with a 
1 mg/ml glucose medium for either 50 min (control chambers) 
or 45 min (experimental chambers). The control chambers 
(thin line) were subsequently followed by perifusion with a 
4 mg/ml arginine (upper) or a 4 mg/ml arginine plus 0.6 mgj 
ml glucose (middle and lower) for 60 min. The experimental 
chambers (thick line) were introduced with alloxan solution 
for 5 min and were followed by a 4 mg/ml arginine (upper) 
or a 4 mg/ml arginine plus 0.6 mg/ml glucose (middle and 
lower). Upper: 20 mg% alloxan exposure in the experimental 
chambers. Middle: 20 mg% alloxan exposure in the experi- 
mental chambers. Lower: 40 mg% alloxan exposure in the 
experimental chambers. 
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Table 1 
Effect of alloxan on arginine- and leucine-induced insulin secretion 
Group of Experiment 5 Mln exposure to 
alloxan (mg%) 
Insulin secretion Effect Secretion 
(mu/100 islets/60 min) P Values (%I 
Mean f S.E. 
I Leucine 0 8.61 + 0.50 (4)b 100 
20 4.50 f 0.87 (4) P<O.OlC 52 + 10 
II Leucine 0 8.08 f 0.31 (4) 100 
40 3.13 f 0.06 (4) P<O.OOl 39* 1 
III Arginine 0 4.64 + 0.41 (4) 100 
20 4.25 * 0.21 (4) P<O.40 92+ 6 
IV Arginine-glucose 0 8.56 f 0.67 (4) 100 
20 8.22 f. 0.77 (4) P<O.70 96+- 9 
V Arginine-glucose 0 8.52 + 0.52 (5) 100 
40 7.42 f 0.34 (5) P<O.lO 81* 4 
aControl chambers were initially perifused with a 1 mg/ml glucose medium for 50 min, then with a 4 mg/ml * 
medium of leucine, arginine or arginine plus glucose (0.6 mg/ml) for 60 min. Experimental chambers were 
initially perifused with a 1 mg/ml glucose medium for 45 min, then with alloxan solution (20 mg% or 
40 mg%) for 5 min, followed by a 4 mg/ml medium of leucine, arginine of arginine plus glucose (0.6 mg/ml) 
for 60 min. 
bNumbers in parentheses are the numbers of the experiments 
‘P values by paired t-test 
levels of glucose to arginine solution markedly augment- 
ed insulin secretion both in perfused isolated pancreas 
[8, lo] and perifused isolated islets [ 121. 
The present results of insulin secretion, by arginine 
alone, showed a small but apparent biphasic pattern, 
probably due to the higher concentration of arginine 
18.98 mM (4 mgjml) used than 15 mM (2.6 mg,/ml) 
[l] as well as to a subtle difference in the procedure 
used in isolating rat islets. Arginine-induced insulin 
secretion is not accompanied by an elevation of islet 
tissue CAMP levels, while glucose- and tolbutamide- 
induced insulin secretion is modulated at least partially 
through increased CAMP levels of islets, particularly 
the initial phase of insulin secretion [l] . The initial 
phase of glucose-induced insulin secretion was accom- 
panied by the elevated cyclic adenosine 3,5-mono- 
phosphate (CAMP) levels in isolated islets [ 1,131. 
Tolbutamide increased islet tissue CAMP levels by 
decreasing phosphodiesterase activity [ 151. The increas- 
ed phosphodiesterase activity by arginine may corre- 
spond to the non-elevated levels of CAMP during 
arginine-induced insulin secretion [14] . If arginine 
stimulates insulin secretion through a mechanism 
other than adenylate cyclase-CAMP system, this will 
be the system which is not affected by prior exposure 
to alloxan as documented in this study. 
Amino acids appear to stimulate insulin release by 
binding to a specific transport molecule on the beta 
cell membrane [ 15 ] . Each individual amino acid should 
be further studied for its insulinotropic mechanism, since 
there is an essential difference between arginine and 
leucine in terms of insulin secretion after prior exposure 
to alloxan. 
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